Carregando...
Developing a genetic signature to predict drug response in ovarian cancer
There is a lack of personalized treatment options for women with recurrent platinum-resistant ovarian cancer. Outside of bevacizumab and a group of poly ADP-ribose polymerase inhibitors, few options are available to women that relapse. We propose that efficacious drug combinations can be determined...
Na minha lista:
| Publicado no: | Oncotarget |
|---|---|
| Principais autores: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals LLC
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5871081/ https://ncbi.nlm.nih.gov/pubmed/29599910 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.23663 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|